Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, and Cancer therapeutics and mechanisms.
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinoma
Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models
DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Unprocessed genomic uracil as a source of DNA replication stress in cancer cells
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer
A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinoma
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells
Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
Cycling cancer persister cells arise from lineages with distinct programs
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity
Targeting the DNA replication stress phenotype of KRAS mutant cancer cells
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
Screening and Validation of Molecular Targeted Radiosensitizers
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR Dependency
Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors